Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20499601 | 0.89 | DRD2 (0.44) | DRD2DRD3HTR1A | |
| SCHEMBL8538844 | 0.82 | DRD2 (0.65) | DRD2DRD3HTR1A | |
| SCHEMBL357358 | 0.82 | DRD2 (0.65) | DRD2DRD3HTR1A | |
| SCHEMBL4536932 | 0.82 | DRD2 (0.65) | DRD2DRD3HTR1A | |
| SCHEMBL1626963 | 0.82 | DRD2 (0.65) | DRD2DRD3HTR1A | |
| SCHEMBL1492682 | 0.82 | DRD2 (0.56) | DRD2DRD3HTR1A | |
| SCHEMBL134338 | 0.81 | DRD2 (0.54) | DRD2DRD3 | |
| SCHEMBL28845061 | 0.81 | DRD2 (0.63) | DRD2DRD3HTR1A | |
| Hydrochloric Acid SCHEMBL1711121 | 0.81 | DRD2 (0.63) | DRD2DRD3HTR1A | |
| SCHEMBL503067 | 0.81 | DRD2 (0.54) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115710234-B | 3,4, 5-trisubstituted isoxazole compound with anti-tumor activity and preparation method and application thereof | 华南理工大学 | 2024-04-16 | — | — | CN | claimed |
| US-20240101558-A1 | AMPK ACTIVATORS | KALLYOPE, INC. | 2024-03-28 | — | — | US | claimed |
| EP-4069693-B1 | HYDROPYRIDO[1,2-ALPHA]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | HOFFMANN LA ROCHE (CH) | 2024-03-20 | — | — | EP | claimed |
| US-11851429-B2 | AMPK activators | KALLYOPE, INC. (US) | 2023-12-26 | — | — | US | claimed |
| EP-3953356-B1 | HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-07-26 | — | — | EP | claimed |
| CN-116323608-A | AMPK activator | 卡尔优普公司 | 2023-06-23 | — | — | CN | claimed |
| EP-4153589-A1 | AMPK ACTIVATORS | Kallyope, Inc. (US) | 2023-03-29 | — | — | EP | claimed |
| CN-115710234-A | 3,4,5-trisubstituted isoxazole compounds with antitumor activity and preparation method and application thereof | 华南理工大学 | 2023-02-24 | — | — | CN | claimed |
| US-20230034723-A1 | HYDROPYRAZINO[1,2-D][1,4]DIAZEPINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-02-02 | — | — | US | claimed |
| CN-112876420-B | Thiobenzoyl derivative and application thereof | 沈阳化工研究院有限公司 | 2023-01-24 | — | — | CN | claimed |
| EP-0975633-A1 | 5,6,7-TRISUBSTITUTED-4-AMINOPYRIDOL 2,3-D]PYRIMIDINE COMPOUNDS | Abbott Laboratories (US) | 2000-02-02 | — | — | EP | claimed |
| EP-0871444-A4 | 2,5-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 1999-01-13 | — | — | EP | claimed |
| WO-1998046604-A1 | 5,6,7-TRISUBSTITUTED-4-AMINOPYRIDOL[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 1998-10-22 | — | — | WO | claimed |
| WO-1998046605-A1 | 5,7-DISUBSTITUTED 4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS ADENOSINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 1998-10-22 | — | — | WO | claimed |
| WO-1998046603-A1 | 6,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 1998-10-22 | — | — | WO | claimed |
| EP-0871444-A1 | 2,5-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 1998-10-21 | — | — | EP | claimed |
| EP-0863757-A4 | — | — | 1998-09-16 | — | — | EP | claimed |
| EP-0863757-A1 | 2-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 1998-09-16 | — | — | EP | claimed |
| WO-1997005877-A1 | 2-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 1997-02-20 | — | — | WO | claimed |
| WO-1997005878-A1 | 2,5-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 1997-02-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851429-B2 | AMPK activators | PRKAG1, PRKAG2, PRKAG3 | DRD2 4136/4885DRD3 4141/4885HTR1A 2007/4885 |
| US-20230034723-A1 | HYDROPYRAZINO[1,2-D][1,4]DIAZEPINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HRH3, HRH4, HRH2 | DRD2 209/4885DRD3 146/4885HTR1A 760/4885 |
| US-20240101558-A1 | AMPK ACTIVATORS | PRKAG1, PRKAG2, PRKAG3 | DRD2 4136/4885DRD3 4141/4885HTR1A 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.